DNTH
Dianthus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$108.10
+0.23%Aug 4, 2026, 20:01 UTC
Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.
Source:Aug 4, 2026, 20:01 UTC
Dianthus Therapeutics is advancing DNTH212 for Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis, with Phase 1 healthy volunteer data anticipated by year-end 2026.
Source:Aug 4, 2026, 20:01 UTC
Dianthus Therapeutics reported that the Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy exceeded its original enrollment target of 36 patients, with top-line results from 46 patients on track for December 2026.
Source:Aug 4, 2026, 20:01 UTC
Dianthus Therapeutics reported a 75% response rate in the interim responder analysis from the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by year-end 2026.
Source:Aug 4, 2026, 20:01 UTC
Dianthus Therapeutics initiated the Phase 3 EMERGE registrational trial of claseprubart in generalized Myasthenia Gravis in June 2026, with top-line results anticipated in the second half of 2028.
Source:Aug 4, 2026, 20:01 UTC
Dianthus Therapeutics reported its Q2 2026 financial results, highlighting approximately $1.2 billion in cash as of June 30, 2026, with expected runway into 2030.
Source:Jun 12, 2026, 17:20 UTC
Dianthus Therapeutics reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).
Source: